










??????R978.1       ??????A
Advances in bacterial drug resistance and new antimicrobial therapy
Yao Wen-ye, Zeng Jie, Xue Yun-xin and Wang Dai
(State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Xiamen University, Xiamen 361102)
Abstract    Traditional antibiotics can block conserved bacterial signaling pathway or metabolic pathway, and 
therefore it is unable to distinguish bacteria. Long-termed usage will lead to dysbacteriosis and drug resistance. We 
need to fi nd a new antibacterial drug which can target pathogens and drug-resistant bacteria specifi cally. By reviewing 
current research progress, this paper mainly discussed the mechanisms of traditional antibiotics and bacterial drug-
resistance. We summarized a series of traditional and new antimicrobial therapies for solving bacterial drug-resistance, 
including the application of CRISPR-Cas9 system, a popular gene editing tool, as a gene-specifi c bactericidal drug.
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Tab. 1    The types and target of traditional antibiotic


























































































































































































2.5    CRISPR-Cas9??
CRISPR-Cas system(clustered regularly interspaced 
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